Caplight Logo









BioSyngen

BioSyngen

Private
SingaporeHealthcare & Life Scienceshttps://biosyngen.com

Last Round

Early Funding

Oct 20, 2021

Total Funding Raised

$43.5M

Company Overview

BioSyngen is a biotechnology company that develops first-in-class cell therapies, including CAR-T, TCR-T, and TILs, to treat solid tumors and other cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

cell and gene therapyCAR-T therapycancer immunotherapyT-cell therapyCGTsolid tumor treatmentTCR-T therapyTIL therapyTumor-Infiltrating Lymphocytesautologous cell therapyGMP manufacturingGood Manufacturing Practiceclinical-stage biotechEBV-positive cancersnasopharyngeal carcinomaautomated cell manufacturingantigen discoveryOrphan Drug Designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioSyngen Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

BioSyngen Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingOct 20, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Hao Shen

President & CEO

Executive Team

BioSyngen Investors

Notable investors and investment history

InvestorRounds
Science City (Guangzhou) Investment Group Co., Ltd.Early Funding
View all Investors

BioSyngen Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BioSyngen Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BioSyngen's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range19
Year Founded2016
Last FundingOct 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.